PharmaBlock Sciences (Nanjing) (300725) Stock Overview
Provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
300725 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
PharmaBlock Sciences (Nanjing), Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥34.36 |
| 52 Week High | CN¥53.54 |
| 52 Week Low | CN¥27.07 |
| Beta | 0.65 |
| 1 Month Change | -15.66% |
| 3 Month Change | -12.28% |
| 1 Year Change | -2.69% |
| 3 Year Change | -55.85% |
| 5 Year Change | -71.71% |
| Change since IPO | 434.37% |
Recent News & Updates
Recent updates
PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Looks Just Right With A 29% Price Jump
Feb 10
PharmaBlock Sciences (Nanjing) (SZSE:300725) Takes On Some Risk With Its Use Of Debt
Nov 22PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) P/E Is Still On The Mark Following 40% Share Price Bounce
Sep 30PharmaBlock Sciences (Nanjing)'s (SZSE:300725) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Aug 23We Think PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Taking Some Risk With Its Debt
Jul 31PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Increasing Its Dividend To CN¥0.31
Jun 12PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Apr 21PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Looks Just Right With A 25% Price Jump
Mar 07Shareholder Returns
| 300725 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -7.7% | -7.3% | -8.1% |
| 1Y | -2.7% | 5.1% | 16.4% |
Return vs Industry: 300725 underperformed the CN Pharmaceuticals industry which returned 5.1% over the past year.
Return vs Market: 300725 underperformed the CN Market which returned 16.4% over the past year.
Price Volatility
| 300725 volatility | |
|---|---|
| 300725 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in CN Market | 10.2% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 300725 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300725's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 2,330 | Minmin Yang | www.pharmablock.com |
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, DNA encoded library technology, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and full time equivalent (FTE). The company also provides small molecule drug substance CDMO services, including optimal route scouting; FFS and FTE for process research and development of RSMs, intermediates, and APIs; impurity studies and synthesis; solid state chemistry; analytical development and quality control; cGMP manufacturing of intermediates and APIs; and CMC regulatory filing support.
PharmaBlock Sciences (Nanjing), Inc. Fundamentals Summary
| 300725 fundamental statistics | |
|---|---|
| Market cap | CN¥8.00b |
| Earnings (TTM) | CN¥201.14m |
| Revenue (TTM) | CN¥1.98b |
Is 300725 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300725 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.98b |
| Cost of Revenue | CN¥1.41b |
| Gross Profit | CN¥573.89m |
| Other Expenses | CN¥372.75m |
| Earnings | CN¥201.14m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 22, 2026
| Earnings per share (EPS) | 0.86 |
| Gross Margin | 28.99% |
| Net Profit Margin | 10.16% |
| Debt/Equity Ratio | 1.4% |
How did 300725 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/24 17:17 |
| End of Day Share Price | 2026/03/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PharmaBlock Sciences (Nanjing), Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Hanyang Huang | Industrial Securities Co. Ltd. |
| Song Yang | Tianfeng Securities Brokerage Co., Ltd |